Buy Rating Affirmed for Arvinas Holding Company on Strong Clinical Trial Results and Competitive Market Positioning
Express News | HC Wainwright & Co. Reiterates Buy on Arvinas, Maintains $87 Price Target
Arvinas Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/17/2024 170.86% HC Wainwright & Co. → $87 Reiterates Buy → Buy 05/09/2024 86.8% Wells Fargo $63 → $60 M
Buy Rating on Arvinas for Promising Breast Cancer Therapy and Market Potential
Express News | Arvinas Inc : Jefferies Cuts Target Price to $60 From $66
Analysts Offer Insights on Healthcare Companies: Arvinas Holding Company (ARVN), Longeveron (LGVN) and EDAP TMS (EDAP)
Analysts Conflicted on These Healthcare Names: Zimmer Biomet Holdings (ZBH), Doximity (DOCS) and Arvinas Holding Company (ARVN)
Form 144 | Arvinas(ARVN.US) Insider Proposes to Sell 1.16 Million in Common Stocks
SEC FILLINGS DISCLOSED/ May 16, $Arvinas(ARVN.US)$ Insider Sean Cassidy intends to sell 35,000 shares of its common stock on May 16, with a total market value of approximately $1.16 million. Sean C
Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Arvinas Holding Company (ARVN) and Progyny (PGNY)
Walmart Posts Upbeat Earnings, Joins Canada Goose, Lightspeed Commerce And Other Big Stocks Moving Higher On Thursday
U.S. stocks were higher, with the Dow Jones gaining over 50 points on Thursday.Shares of Walmart Inc. (NYSE:WMT) rose sharply during Thursday's session following better-than-expected quarterly earning
Sector Update: Health Care Stocks Steady Premarket Thursday
Health care stocks were steady premarket Thursday, with the iShares Biotechnology ETF (IBB) inactive and the Health Care Select Sector SPDR Fund (XLV) up 0.1%. Arvinas (ARVN) shares were up more than
Sector Update: Health Care
Health care stocks were mixed premarket Thursday, with the iShares Biotechnology ETF (IBB) recently down 0.3% and the Health Care Select Sector SPDR Fund (XLV) inactive. Arvinas (ARVN) was up more tha
Arvinas and Pfizer Breast Cancer Trial Shows Promising Results
Express News | Arvinas Inc: Safety Profile of Vepdegestrant in Combination With Palbociclib Were Consistent With Data Previously Reported at Sabcs in Dec
Express News | Arvinas: At Recommended Phase 3 Dose of 200 Mg Vepdegestrant Plus Palbociclib, Patients Achieved a Median Progression-Free Survival of 13.9 Months
Express News | Arvinas and Pfizer Announce Updated Clinical Data From Phase 1B Trial of Vepdegestrant in Combination With Palbociclib (Ibrance®)
Arvinas and Pfizer Announce Updated Clinical Data From Phase 1b Trial of Vepdegestrant in Combination With Palbociclib (IBRANCE)
– After six months of additional follow-up, clinical benefit rate (63%), overall response rate (41.9%), median progression-free survival (11.2 months), and safety profile of vepdegestrant in combinati
Form 144 | Arvinas(ARVN.US) Insider Proposes to Sell 835.1K in Common Stocks
SEC FILLINGS DISCLOSED/ May 15, $Arvinas(ARVN.US)$ Insider Sean Cassidy intends to sell 25,000 shares of its common stock on May 15, with a total market value of approximately $835.1K. Sean Cassidy
NEXTracker Posts Upbeat Earnings, Joins Monday.com, Nu Holdings And Other Big Stocks Moving Higher On Wednesday
U.S. stocks were higher, with the Dow Jones gaining around 150 points on Wednesday.Shares of Nextracker Inc. (NASDAQ:NXT) rose sharply during Wednesday's session after the company reported better-than
Form 144 | Arvinas(ARVN.US) Officer Proposes to Sell 480K in Common Stocks
SEC FILLINGS DISCLOSED/ May 13, $Arvinas(ARVN.US)$ Officer Sean Cassidy intends to sell 15,000 shares of its common stock on May 13, with a total market value of approximately $480K. Sean Cassidy ha